Imiglucerase

證據等級: L5

預測適應症: 5 個

Imiglucerase: From Gaucher Disease to Hurler Syndrome

One-Sentence Summary

Imiglucerase (DrugBank DB00053) is a recombinant enzyme replacement therapy whose established use is Gaucher disease, where it substitutes for deficient glucocerebrosidase. The TxGNN model predicts it may also be effective for Hurler Syndrome (MPS I), but this is currently supported only by 0 clinical trials and 2 general (non-disease-specific) review articles.

Quick Overview

Item	Content
Original Indication	Gaucher Disease (per cited literature context; not confirmed by formal regulatory/label data in this pack)
Predicted New Indication	Hurler Syndrome
TxGNN Prediction Score	99.52%
Evidence Level	L4
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for imiglucerase is not available in this evidence pack (flagged as a High-severity data gap). Based on known information, imiglucerase belongs to the enzyme replacement therapy (ERT) class; its efficacy in Gaucher disease — via replacement of deficient glucocerebrosidase to clear glucocerebroside accumulation — is well established.

However, the mechanistic case for Hurler syndrome is weak. Hurler syndrome (MPS I) results from a deficiency of a different enzyme, alpha-L-iduronidase (IDUA), which clears glycosaminoglycans rather than glucocerebroside. The two supporting literature items (PMID 20534487, 21211680) are general reviews of “ERT for lysosomal storage diseases” as a therapeutic class — neither provides evidence specific to imiglucerase treating Hurler syndrome. The high TxGNN score most likely reflects the model clustering imiglucerase with other LSD-targeted ERT drugs by embedding similarity, rather than capturing a true drug-specific, disease-specific mechanistic link.

The same pattern holds for the other candidates in this evidence pack (Scheie syndrome, benign adrenal neoplasm, autosomal ichthyosis, cholesteryl ester storage disease) — all scored similarly high (L5, “Hold”) with no literature or trials specific to imiglucerase, and in several cases a distinct causal enzyme already exists with its own approved ERT (e.g., sebelipase alfa for cholesteryl ester storage disease).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20534487	2010	Review/Imaging	PNAS	General overview of ERT (including imiglucerase) across LSDs — Gaucher, Fabry, Hurler, Hunter, Maroteaux-Lamy, Pompe — not specific to imiglucerase-Hurler efficacy
21211680	2010	Review	La Revue de medecine interne	History/overview of ERT development starting with alglucerase/imiglucerase for Gaucher disease; broad LSD-ERT class review, no Hurler-specific data

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN similarity score, there are no clinical trials and no disease-specific literature supporting imiglucerase for Hurler syndrome. The proposed mechanistic link is questionable, since Hurler syndrome and Gaucher disease involve different deficient enzymes (IDUA vs. glucocerebrosidase) and different substrates.

To proceed, the following is needed:

TFDA/label warnings and contraindications (currently a Blocking data gap — required before any S1 safety review)
Confirmed mechanism of action data for imiglucerase
Preclinical or case-level evidence directly linking glucocerebrosidase replacement to MPS I/Hurler pathology
Re-evaluation of the other four predicted indications in this pack (Scheie syndrome, adrenal neoplasm, ichthyosis, cholesteryl ester storage disease), all of which currently have weaker (L5) evidence than the top-ranked candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.